anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises compounds of the general formula <FORM:0992737/C2/1> wherein R1 represents an alkyl group having a chain length of at least 9 carbon atoms and containing from 9 to 22 carbon atoms and R2 represents an alkyl group having a chain length of from 1 to 10 carbon atoms, and salts thereof. The compounds are prepared by treating a compound of the general formula <FORM:0992737/C2/2> wherein R3 represents an esterified carboxyl group, R10 represents an alkyl or alkenyl group having a chain length of at least 9 carbon atoms and containing from 9 to 22 carbon atoms and R20 represents an alkyl or alkenyl group having a chain length of not more than 10 carbon atoms, in any desired sequence with a reducing agent and with a hydrolysing agent and then converting the resulting amino-substituted carboxylic acid into a salt if desired. The cyano-compounds used as starting materials can be prepared by reacting the sodium salt of the corresponding cyano-acetic ester, in the presence of excess cyano-acetic ester, in alcohol with an R10 halogenide in which R10 is as defined above, followed by the introduction of R20 into the resultant monosubstituted cyano-acetic ester in a similar manner.  Examples are given.ALSO:Compounds of the general formula <FORM:0992737/C4-C5/1> wherein R1 represents an alkyl group having a chain length of at least 9 carbon atoms and containing from 9 to 22 carbon atoms and R2 represents an alkyl group having a chain length of from 1 to 10 carbon atoms, are used as thickening or gelation agents for non-polar or slightly polar organic solvents which are used, for example, in lacquers, paints, lubricating oils and stain-cleansing agents.  Specified organic solvents are petrol, petroleum ethers methylene chloride, chloroform, carbon tetrachloride, benzene, toluene, xylene, nitrobenzene, diethyl ether and dioxane.  Example 1 describes a thixotropic base material, suitable for lacquers and colours, containing petroleum ether and a - dodecyl - a  - propyl - b  - amino - propionic acid.  Example 4 describes viscous oils, suitable for use for lubrication purposes, comprising thinly liquid paraffin oil and a -hexadecyl-a  - propyl - b  - amino - propionic acid.
A method for preparing veterinary product Trutenat for correction of the estrous cycle in mammals and prevention of parturition and surgical pathology provides for keeping the raw material for 2-8 days at the temperature of 2- followed by its chopping and mixing with 1-3 parts of sterile diluent. The mixture is kept for 1-4 hours at the temperature of 15- followed by heating on water bath at the temperature of 60-. The solid fraction is collected. The product is sterilized in autoclave for 90 minutes. As raw material, the tissues of the male-bee larvae (aged 5-7 days) are used. The tissues are chopped without washing and without denaturation.
To drink the hibiscus tea for 10 weeks. At the beginning of the trial (week zero), the second week, the sixth week, and the tenth week after stopping drinking, the visual fatigue scale, blood pressure, and body composition were examined respectively. At the initial stage (0th week) and at the 10th week after stopping drinking, visual acuity examinations were performed.
BACKGROUND AND OBJECTIVE: Core decompression surgery is an effective treatment method for patients with pre-collapse osteonecrosis of the femoral head (ONFH). The treatment relies on accurately predrilling the wire into the necrotic lesion. However, the surgical planning of this drilling path remains unclear. This paper aims to develop a framework to automatically plan the drilling path and analyze its geometric parameters.
METHODOLOGY: The proposed system consists of two stages. The first stage is to detect the key points. Besides the entry point and target point for the drilling path, the center of the femoral head (FH) and the boundary points of the necrotic lesion are also detected for the subsequent geometric analysis. In the second stage, the geometric parameters of the drilling path are analyzed, including the size of the necrotic lesion, the length from the entry point to the target point, the relative location between the FH center and the necrosis center, and the angular range of the drilling path in the anterior-posterior (AP) direction and superior-inferior (SI) direction.
RESULTS: All of the drilling paths designed by the proposed system were considered successful, starting from the proximal subtrochanteric region, terminating at the center of the necrotic lesion, and remaining within the femoral neck. The relative coordinates of the centers of the femoral head and necrotic lesion were (-0.89,5.14,2.63) mm for the left femurs and (1.55,5.92,2.63) mm for the right femurs, on average. The angular range of the drilling path was 39.99±29.58 degrees in the SI direction and 46.18±40.73 degrees in the AP direction.
CONCLUSION: This study develops a framework that allows for automatic planning and geometric analysis of the drilling path in core decompression surgery. The target point of the drilling path primarily resides in the lateral-anterior-superior region relative to the femoral head center. Surgeons and researchers can benefit from our unified framework while still maintaining the flexibility to adapt to variations in surgical cases.
This is a prospective, non-randomized, single center study designed to measure and determine the changes in cerebral blood flow in a cohort of single ventricle patients followed across all three stages of surgical (Fontan) reconstruction. In addition, cerebral blood flow response to hypercarbia will be determined after the first 2 operations as a measure of cerebral blood flow reserve and the "intactness" of the cerebral autoregulatory system. MRI data from this cohort will be compared with that collected in age-matched healthy children and in a cross sectional group of patients who will not necessarily be followed through all stages of surgery, but may undergo one or two of the MRI evaluations depending on their stage of surgery. Neurological exams and EEGs will be performed. Medical history, cardiac catheterization data, where available, will also be collected. Factors such as cardiopulmonary bypass time and socioeconomic class will be controlled for.
Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative condition of the central nervous system (CNS) and is considered the most common cause of disability in young adults. It is estimated that the number of adults with MS in the UK has risen to 131,720. The majority of patients (85%) have Relapsing Remitting MS (RRMS), with many later entering the secondary progressive phase (SPMS). Relapse is the cardinal clinical feature of RRMS, and can be also prevalent in SPMS, however the influence of relapses on the long-term disability is not yet fully defined and remains controversial.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019 and Covid-19, a disease caused by SARS-CoV-2 became a pandemic in March 2020. The impact of SARS-CoV-2 infection on patients with MS has yet to be elucidated. The main focus of previous studies has been the actual risk of Covid-19 inpatients with MS, the risk of MS exacerbation during Covid-19 infection and the impact of disease modifying drugs (DMDs) in the severity of Covid-19 infection. Other studies have explored the psychological and behavioural impact of Covid-19 pandemic to MS patients; those studies highlighted the risks from missing/cancelling clinic appointments and MRIs, missing/stopping/changing DMDs, delays in DMDs infusions, having a relapse and not seeking medical advice or disruptions in rehabilitation services. To the best of our knowledge, there is currently no study that explored the effect of Covid-19 on MS patients by looking systematically into MS relapses and their potential consequences. We will study the occurrence and subsequent management of relapses occurring between April - June 2020 at the peak of the first wave of the pandemic, compared to individuals who have relapsed during the same period in 2019. This observational, retrospective study will be performed at 5 UK sites.
<P>PROBLEM TO BE SOLVED: To provide a material suitable for a watch, glasses, accessories, etc. by which a user can receive medical effect of a hot spring with an unconscious feeling without going out to a hot spring.  <P>SOLUTION: This hot spring powder material is a material for manufacturing a member for an attachment to be attached on a watch, glasses, accessories, or another member to be attached on a human body or clothes to come into contact with a human body. The hot spring powder containing material is manufactured by making hot spring powder or a mixture of hot spring powder and ceramics powder with a far-infrared rays radiating function etc. be contained in the material in a manufacturing process of one kind selected from a metal, a ceramic, glass, synthetic resin, and rubber.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND AND AIMS: Hospitalized patients often have acute kidney disease (AKD) or chronic kidney disease (CKD), with important metabolic and nutritional consequences. Moreover, in case kidney replacement therapy (KRT) is started, the possible impact on nutritional requirements cannot be neglected. On this regard, the present guideline aims to provide evidence-based recommendations for clinical nutrition in hospitalized patients with KD.
METHODS: The standard operating procedure for ESPEN guidelines was used. Clinical questions were defined in both the PICO format, and organized in subtopics when needed, and in non-PICO questions for the more general topics. The literature search was from January 1st, 1999 until January 1st, 2020. Each question led to one or more recommendation/statement and related commentaries. Existing evidence was graded, as well as recommendations and statements were developed and agreed upon in a multistage consensus process.
RESULTS: The present guideline provides 32 evidence-based recommendations and 8 statements, defining how to assess nutritional status, how to define patients at risk, how to choose the route of feeding, and how to integrate nutrition with KRT. In the final online voting, a strong consensus was reached in 84% at least of recommendations and 100% of statements.
CONCLUSION: The presence of KD in hospitalized patients identifies a highly heterogeneous group of subjects with widely varying nutrient needs and intakes. Considering the high nutritional risk related with this clinical condition, an individualized approach consisting of nutritional status evaluation and monitoring, frequent evaluation of nutritional requirements, and careful integration with KRT should be planned to avoid both underfeeding and overfeeding. Practical recommendations and statements were developed, aiming at defining suggestions for everyday clinical practice in the individualization of nutritional support in this patient setting. Literature areas with scarce or without evidence were also identified, thus requiring further basic or clinical research.
To support quick decision making in team medical care.SOLUTION: A medical information processing apparatus according to an embodiment has a message acquisition unit, a role acquisition unit, a progress acquisition unit, a candidate specification unit, and a display control unit. The message acquisition unit acquires, in a channel opened in a chat application for discussing a target medical care, a message history that is the history of messages already input by a plurality of members of the channel. The role acquisition unit acquires role information representing a role of a target member of the plurality of members. The progress acquisition unit acquires progress information representing the current progress of the target medical care. The candidate specification unit specifies one or more candidates related to the messages input by the target member based on the message history, the role information and/or the progress information. The display control unit displays the one or more candidates on an input screen related to the channel displayed for the target member.SELECTED DRAWING: Figure 2
An implant ( 5, 13 ) and/or a unit ( 9 ), e.g. spacer sleeve, belonging to said implant is/are intended to extend through a hole ( 4 ′) formed in a jaw bone ( 2 ) and through soft tissue ( 3 ) belonging to the jaw bone and to comprise one or more outer layers of principally titanium dioxide. Each layer consists of crystalline titanium dioxide which largely or completely assumes the anatase phase. The invention also relates to a method for production of such a dental implant ( 5, 13 ) and/or of a unit ( 9 ) belonging to it, which has one or more outer layers of titanium dioxide. The method is an anodic oxidation method in which the part or parts bearing the outer layer(s) is/are applied to electrolyte under voltage, e.g. comprising sulfuric acid and phosphoric acid, and the voltage (U) and the dwell time of the part or parts in the electrolyte are chosen such that titanium dioxide, largely or completely assuming the crystalline anatase phase, is formed. Excellent bone guidance and soft tissue integration can be achieved in this way.
Approximately 10 subjects with Alzheimer disease (AD) and 8 healthy control (HC)subjects will be recruited to participate in this study. All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations. Subjects will be asked to undergo a bolus injection of \[18F\]-FMH3. Subjects will undergo serial PET imaging scans and plasma sampling for measurement of \[18F\]-FMH3 in plasma (both protein bound and free) over a period of up to 8 hours. The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, \[18F\]-FMH3.

At least 2 weeks following the initial imaging visit, subjects may be asked to return for a second injection and scanning procedure to evaluate the reproducibility of the imaging measure using this procedure. Subjects may decline to participate in the second scan.
The invention discloses a traditional Chinese medicine composition for treating chronic pyelitis. Chinese medical science considers that chronic pyelitis belongs to the scope of stranguria, and has the main characteristics of lumbago, frequent micturition, urgent urination, odynuria, lower abdominal pain, fever, aversion to cold, proteinuria or hematuresis. A method of diagnosis and treatment based on an overall analysis of the illness and the patient's condition is adopted in traditional Chinese treatment, and the therapeutic principle is focus on clearing away heat and toxic materials as well as promoting dieresis and treating stranguria, assisting by tonifying kidney, strengthening health, promoting blood circulation, removing blood stasis, and strengthening the body resistance to eliminate pathogenic factors so as to improve the immunity of an organism. According to the traditional Chinese medicine composition for treating chronic pyelitis, traditional Chinese medicines such as smooth stylose staff-tree, rhododendroa microphyton franch, jasminum laurifolium, poria cocos, astragalus mongholicus, codonopsis pilosula, bighead atractylodes rhizome, gorgon fruit, teasel root, solomon's seal and Chinese yam are selected to prepare decoction for administration to patients. Clinical experiments in our hospital show that the cure rate and the total effective rate achieve 78.3 percent and 96.6 percent, respectively, which are significantly superior to those of a control group, and time required for returning main symptoms and routine urine test results to the normal level is significantly shorter than that of the control group. The traditional Chinese medicine composition for treating chronic pyelitis is worth clinical generalization.
PROBLEM TO BE SOLVED: To industrially produce a histamine derivative which is a synthetic raw material for imidazopyridine derivatives useful as a preventing or a therapeutic agent for hypertension at a low cost on a large scale. SOLUTION: An N protected imidazole compound represented by formula I (R<1> is H or an alkyl; R<2> is a protecting group) is reacted with an equimolar or an excessive amount of oxirane to afford a 5(4)-hydroxyethyl-imidazole compound represented by formula II (R<1> and R<2> are each same as those described above). The reaction is usually carried out under cooling conditions or at ambient temperature for several tens of minutes to some ten hours.  The resultant compound is then halogenated with a halogenating agent such as thionyl chloride in an organic solvent such as benzene or toluene under cooling conditions with ice or ambient temperature and subsequently reacted with phthalimide, etc., to provide a compound represented by formula III, e.g. a 5(4)-phthalimidoethyl-imidazole compound, which is further treated with acetic acid, etc., to afford an N-(substituted)histamine derivative represented by formula IV or its salt. Furthermore, an imidazopyridine derivative represented by formula V [R<3> is H, a lower alkylsulfonyl or a group represented by the formula C(=Z)R<0> : Z is 0, etc.; R<0> is 1: ring A is phenyl group] is obtained from the resultant compound represented by formula IV according to a well-known method.
Hepatitis B e antigen (HBeAg) seropositivity during the natural history of chronic hepatitis B (CHB) is known to coincide with significant increases in serum and intrahepatic HBV DNA levels. However, the precise underlying mechanism remains unclear. In this study, we found that PreC (HBeAg precursor) genetic ablation leads to reduced viral replication both in vitro and in vivo. Furthermore, PreC impedes the proteasomal degradation of HBV polymerase, promoting viral replication. We discovered that PreC interacts with SUV39H1, a histone methyltransferase, resulting in a reduction in the expression of Cdt2, an adaptor protein of CRL4 E3 ligase targeting HBV polymerase. SUV39H1 induces H3K9 trimethylation of the Cdt2 promoter in a PreC-induced manner. CRISPR-mediated knockout of endogenous SUV39H1 or pharmaceutical inhibition of SUV39H1 decreases HBV loads in the mouse liver. Additionally, genetic depletion of Cdt2 in the mouse liver abrogates PreC-related HBV replication. Interestingly, a negative correlation of intrahepatic Cdt2 with serum HBeAg and HBV DNA load was observed in CHB patient samples. Our study thus sheds light on the mechanistic role of PreC in inducing HBV replication and identifies potential therapeutic targets for HBV treatment.
The invention discloses a moisturizing cosmetic, a moisturizing mask and modified attapulgite. The moisturizing cosmetic comprises 0.2-10 wt% of the modified attapulgite. The moisturizing mask is prepared from the following raw materials in percentage by mass: 1-3% of glycerin, 0.5-1.5% of 1, 3-propylene glycol, 0.2-0.8% of sodium hyaluronate, 5-10% of the modified attapulgite and the balance of water. The modified attapulgite is prepared by the following method: mixing attapulgite and sodium hexametaphosphate aqueous solution, centrifuging, and spray drying; mixing the purified attapulgite, D-glucuronic acid and caprylyl glycine, and drying to constant weight. The modified attapulgite prepared by the invention has good adsorption capacity and water retention performance, and excellent antibacterial performance, and is particularly suitable for application in cosmetics. The moisturizing cosmetic prepared by the invention has excellent moisturizing performance. The moisturizing cosmetic can be astringent, whitening water, moisturizing cream, facial mask, skin lotion and the like.
Nonalcoholic steatohepatitis (NASH) is an inflammatory and fibrotic liver disease that has reached epidemic proportions and has no approved pharmacologic therapies. Research and drug development efforts are hampered by inadequate preclinical models. This research describes a three-dimensional bioprinted liver tissue model of NASH built using primary human hepatocytes and nonparenchymal liver cells (hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) from either healthy or NASH donors. Three-dimensional tissues bioprinted with cells sourced from diseased patients showed a NASH phenotype, including fibrosis. More importantly, this NASH phenotype occurred without the addition of disease-inducing agents. Bioprinted tissues composed entirely of healthy cells exhibited significantly less evidence of disease. The role of individual cell types in driving the NASH phenotype was examined by producing chimeric bioprinted tissues composed of healthy cells together with the addition of one or more diseased nonparenchymal cell types. These experiments reveal a role for both hepatic stellate and liver sinusoidal endothelial cells in the disease process. This model represents a fully human system with potential to detect clinically active targets and eventually therapies.
First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
For resectable colorectal cancer (CRC), the standard treatment is perioperative adjuvant treatment and complete resection. For unresectable CRC, the standard treatment is systemic chemotherapy. The detection of promising biomarkers is necessary for optimizing the management of CRC and improving patient survival. If physicians can detect useful biomarkers, patients with CRC may benefit from more aggressive or less toxic treatment. Recent studies have shown that the inflammatory and nutritional status both influence the short and long-term oncological outcomes of patients with CRC during perioperative and/or chemotherapy. The utility of several tools for the evaluation of the inflammation and nutritional status has been reported. The introduction of such tools in the management of CRC could have a beneficial impact on postoperative surgical complications or adverse events of chemotherapy. An understanding of the characteristics of each of these evaluations is necessary for their introduction in daily clinical practice. The present report summarizes the background and current status of nutrition and inflammation evaluation tools and future perspectives on their application in the management of patients with CRC.